C&R US Accelerates IND Success and Expands Cross-Border Partnerships.

Seoul, Korea South, 18th Nov 2025 – Established in 1997 as Korea’s first full-service Contract Research Organization (CRO), C&R Research has played a pioneering role in shaping the nation’s clinical research industry. With nearly 30 years of regulatory and operational expertise, the company has earned the trust of global pharmaceutical and biotech partners. In 2023, C&R Research expanded into the U.S. market with the launch of its subsidiary, C&R US, marking a significant step in its global growth strategy.

 

Jinhak Kim, President of C&R US, presenting global clinical experience at 2025 BIO USA.

 

Connecting the U.S. and Korea in Global Clinical Trials

Now in its second year, C&R US continues to expand its presence through trusted partnerships with U.S.-based pharmaceutical companies, biotechnology firms, and CROs.

The company has successfully supported multiple Investigational New Drug (IND) applications across key therapeutic areas, including atopic dermatitis, solid tumors, biosimilars, and medical devices, while also providing Pre-IND meeting support to help clients design efficient early-stage development strategies.

C&R Research: Gateway to Accelerated Global Market Entry

Korea ranks among the world’s leading destinations for clinical research (6th globally, with Seoul ranked 2nd among cities), supported by advanced hospital infrastructure, high-quality medical standards, and strong patient recruitment capabilities.

Based on internal benchmarking and cost comparisons, the country’s streamlined regulatory framework, featuring parallel IRB and IND review, enables faster study start-up, while overall clinical costs are estimated to be up to 40 – 50% lower than in the United States. Leveraging these advantages, C&R Research serves as a strategic bridge for biopharmaceutical partners aiming for accelerated and cost-effective global market entry.

Driving the Next Frontier: AI-Powered ‘Data CRO’

Beyond traditional CRO services, C&R Research collaborates with its subsidiary Trial Informatics (TI) to deliver AI-driven clinical data platforms, including BOIM (CTMS/EDC), ImageTrial, and CsafeR. These platforms integrate predictive analytics throughout the clinical lifecycle, reducing data processing time, optimizing protocol design, and enabling smarter, faster decision-making in global trials.

 

C&R Research Logo.

 

“By combining AI-powered systems with deep regulatory, medical, and statistical expertise, C&R Research delivers an end-to-end clinical solution that accelerates innovation and ensures quality at every stage of the development process,” the company stated.

“We are committed to serving as a trusted gateway for our clients to enter and succeed in global markets.”

For more details contact Jisung Myeong (Brand Marketing Specialist/BMS) from C&R Research Inc. at PR@cnrres.com or visit https://www.cnrres.com/en/.

 

Address: 

• Korea: C&R Building, 412, Yeoksam-ro, Gangnam-gu, Seoul 06199, Republic of Korea
• U.S.: 1 Broadway, 14th Floor, Cambridge, MA 02142, United States

 

Media Contact

Organization: C&R Research Inc.

Contact Person: Jisung Myeong (Brand Marketing Specialist/BMS)

Website: https://www.cnrres.com/en/

Email: Send Email

City: Seoul

Country:Korea South

Release id:37247

The post C&R Research Strengthens Position as Korea’s Leading Global Clinical Trial Hub appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section